Blog

This is tagline here

Begbroke Science Park > News and Press > OXFORD MEDICAL DIAGNOSTICS BREATHES NEW LIFE INTO DIABETES TESTING
Please set your featured image

OXFORD MEDICAL DIAGNOSTICS BREATHES NEW LIFE INTO DIABETES TESTING

Oxford Medical Diagnostics (OMD) has developed a unique breath analysis technology that enables rapid, accurate and low-cost testing for diabetes.

A device designed for use by GPs and other medical professionals is expected to hit the market in the next six to eight months after finishing clinical trials, while a more affordable handheld device for home monitoring could be available within a couple of years.

Oxford Medical Diagnostics moved into the Centre for Innovation and Enterprise, a fully serviced and dedicated business incubator within Oxford University Begbroke Science Park when it opened in 2006.

However, in 2010, they expanded their office and lab space, the result of a merger between OMD, experts in Broadband Cavity Enhanced Absorption Spectroscopy from Oxford University and North East handheld breath-testing start-up EV (Medical Screening). The company’s base at Begbroke allows it to maintain vital links with the University of Oxford and academics around the world.

Oxford Medical Diagnostics has an experienced management team: – CEO and founder, Dr Tony Marchington has a successful track record as a biotechnology entrepreneur, and its board of directors includes Chairman John Jack, a former director of ICI; Gus Hancock, Professor of Chemistry, University of Oxford and the inventor and developer of the CEAS and Broadband technologies; and Michael O’Higgins, current Chairman of the Audit Commission.

The breath analysis technology could equally be applied to the areas of sports studies, dietary studies and recreational fat-burning exercise. It may allow people to get an accurate reading of how much fat they have burnt off during a session in the gym, for example. The technology also has potential for the non-invasive diagnosis of other diseases and conditions, including lung cancer, asthma and renal disease.

OMD Chairman John Jack commented “In 40 years of international business this is without doubt one of the most exciting opportunities with which I have been associated.”



For more information please email info@omdiagnostics.com

Ben Roeves